Page 4 - What is IBAL

IBAL Studies and Research Data Timeline

• Cosme�c Formula�on Sa�sfac�on Survey
2021 • Cosme�c Formula�on Clinical Study of Skin Benefits

• 600+ Anecdotal cases of topical use providing adjunc�ve benefits to mul�ple
indica�ons.

• Redox Poten�al Assay - Oxida�on-Reduc�on Poten�al was measured at 453.2 mV
using method SM2580B
2020 • Ion Gel ZCM-25 Clinical Phase 1 Human Safety Study - 14 day chronic study with no

adverse reac�ons.
• Ion Gel ZCM-25 bacterial reduc�on of 99.9999+% of Staphylococcus Aureus (MRSA)
was determined a�er 30 seconds.
• Ion Gel ZCM-25 fungal reduc�on of 99.95+% of the popula�on of Aspergillus
Brasiliensis was determined a�er 30 seconds.
• Ion Gel ZCM-25 viral elimina�on rate of 99.9999+% of SARS-CoV-2 viral par�cles a�er
10 minutes with extremely low cellular toxicity.
• Dermo absorbancy study on rabbits – chronic dose 14 day.

2019 • Ion Gel ZCM-25 An�microbial 100% kill rate in 30 seconds on these human pathogens
- Aerobic Mesophilic, Fungi, Yeasts, Staphylococcus Aureus, Pseudomonas Aeruginosa.

• Oxygen Radical Absorbance Capacity (ORAC) Ac�vity Assay - ORAC value at 12.5 % is
2018 1025 μM TE/ml - Vitamin C is 133 μmol TE/g at 1:1

• Skin irritability test on rabbits – single dose and mul�-dose - no adverse reac�ons
• ION-ZCM1 In Vitro human cell-based cytotoxicity study - established a safety profile
for topical use at 25% concentra�on.
• ION-ZC1 An�-cancer In Vitro Study - solu�on is responsive cytotoxic agent against
Renal carcinoma, Triple-Nega�ve Breast Cancer and Melanoma cancer cell lines.
• ION-ZC1 In Vitro An�microbial Study On Biofilm - 24 hours at which a prominent
decrease of 50% (average) of biofilm mass was observed over 36 isolates.

• Case Study of topical applica�on trea�ng 20 psoriasis cases ranging from low to high
indexes.
2017 • Case Study 7806 topical applica�on breast cancer stage IV invasive HER2+ ER- PR-
ductal carcinoma.
• Case Study 7830 topical applica�on basal cell carcinoma skin cancer.
• Case Study 7830 topical applica�on squamous cell carcinoma skin cancer.

• ION-ZC1 In Vitro An�microbial Study On MRSA dosing 0.212 – 0.85% (v/v) - higher kill
rates than Vancomycin with less toxicity.
• ION-ZC1 In Vitro An�microbial Study On 12 Hospital Acquired Pathogens
Gram-Nega�ve And Gram-Posi�ve Bacterias And Fungus - 100 % kill rates.
• ION-ZC1 Topical Cream An�-Tumor Efficacy Study Using A Syngeneic 30 Mice
Melanoma Model - its effect was more pronounced as compared to the inhibitory
effect of ALDARA (5% Imiquimod) posi�ve control.

2016 • ION-ZC1 An�-Tumor Efficacy Study By Intravenous Injec�on - IV injec�ons show
massive necrosis, which is not pronounced as much in tumors isolated from the
control.
• ION-ZC1 Acute Intravenous Toxicity In Mice - non-toxic at the dose of 667 mg/kg body
weight on mice.

Personal Care & Nutri�on Clinical Indica�ns Drug Development